title: Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature.
abstract: Sinusoidal obstruction syndrome, a complication occurring early after hematopoietic stem cell transplantation, is a concern for clinicians. There are no guidelines to direct clinicians on the optimal way to prevent and treat this disease. Newer data show that defibrotide is a promising drug both for prevention and treatment, although it is not yet FDA approved.
authors.affiliation: College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA sarah-hopps@ouhsc.edu.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Hopps
authors.affiliation: College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA.
authors.forename: Emily B
authors.initials: EB
authors.lastname: Borders
authors.affiliation: College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA.
authors.forename: Tracy M
authors.initials: TM
authors.lastname: Hagemann
mesh_terms: D000328:Adult; D002648:Child; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage; D065129:Pre-Exposure Prophylaxis / Q000379:methods / Q000592:standards*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide
keywords: Sinusoidal obstructive syndrome; defibrotide; ursodiol; veno-occlusive disease